Advertisement

Topics

Adjuvant Pembrolizumab Reduces Recurrence Risk in High-Risk Resected Stage III Melanoma

09:35 EDT 16 Apr 2018 | Cancer Networks

Dr. Alexander Eggermont presented results of KEYNOTE-045/EORTC 1325-MG, in which melanoma patients with recurrence on placebo can receive pembrolizumab.

Original Article: Adjuvant Pembrolizumab Reduces Recurrence Risk in High-Risk Resected Stage III Melanoma

NEXT ARTICLE

More From BioPortfolio on "Adjuvant Pembrolizumab Reduces Recurrence Risk in High-Risk Resected Stage III Melanoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Melanoma
Melanoma is a highly malignant tumor of melanin-forming cells (melanocytes) There are most commonly found in the skin (resulting from sunlight exposure), but also in the eyes and mucous membranes. Metastasis to other regions of the body is also common....